DE69131292T2 - Antikoagulierende proteine - Google Patents

Antikoagulierende proteine

Info

Publication number
DE69131292T2
DE69131292T2 DE69131292T DE69131292T DE69131292T2 DE 69131292 T2 DE69131292 T2 DE 69131292T2 DE 69131292 T DE69131292 T DE 69131292T DE 69131292 T DE69131292 T DE 69131292T DE 69131292 T2 DE69131292 T2 DE 69131292T2
Authority
DE
Germany
Prior art keywords
factor vii
modified
wild
coagulation cascade
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131292T
Other languages
English (en)
Other versions
DE69131292D1 (de
Inventor
Kathleen Berkner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE69131292D1 publication Critical patent/DE69131292D1/de
Application granted granted Critical
Publication of DE69131292T2 publication Critical patent/DE69131292T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69131292T 1990-01-29 1991-01-25 Antikoagulierende proteine Expired - Fee Related DE69131292T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47131390A 1990-01-29 1990-01-29
PCT/US1991/000552 WO1991011514A1 (en) 1990-01-29 1991-01-25 Anticoagulant proteins

Publications (2)

Publication Number Publication Date
DE69131292D1 DE69131292D1 (de) 1999-07-08
DE69131292T2 true DE69131292T2 (de) 1999-09-30

Family

ID=23871126

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131292T Expired - Fee Related DE69131292T2 (de) 1990-01-29 1991-01-25 Antikoagulierende proteine

Country Status (8)

Country Link
US (2) US5288629A (de)
EP (1) EP0521873B1 (de)
JP (2) JP3330932B2 (de)
AT (1) ATE180834T1 (de)
AU (1) AU651573B2 (de)
CA (1) CA2074839C (de)
DE (1) DE69131292T2 (de)
WO (1) WO1991011514A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JPH05506361A (ja) * 1990-05-17 1993-09-22 ダナ―ファーバー　キャンサー　インスティテュート　インク 多量体蛋白質に対するトランス―ドミナントサプレッサ遺伝子
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
DE69233398D1 (de) * 1991-02-28 2004-09-16 Novo Nordisk As Modifizierter faktor-vii
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
PT699075E (pt) * 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
WO1994028017A1 (en) * 1993-06-01 1994-12-08 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
JPH08511794A (ja) * 1993-06-18 1996-12-10 ハフスルント ニコムド エイ／エス ▲ｖｉｉ▼因子由来ペプチド
US5510248A (en) * 1993-06-22 1996-04-23 The University Of British Columbia Stable recombinant meizothrombin-like polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AR017831A1 (es) 1997-12-10 2001-10-24 Pioneer Hi Bred Int Metodo para alterar la composicion de aminoacidos de una proteina nativa de interes, proteina elaborada, y polinucleotido
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
IL147269A0 (en) 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
AU8755001A (en) 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
CA2420892A1 (en) * 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
AU2002245204A1 (en) * 2000-10-25 2002-07-24 Genzyme Corporation Methods for treating blood coagulation disorders
WO2002038162A1 (en) * 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
RU2338752C2 (ru) 2001-03-22 2008-11-20 Ново Нордиск Хелт Кэр Аг Производные фактора vii свертывания крови
JP4537059B2 (ja) 2001-09-27 2010-09-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
AU2003240438A1 (en) 2002-06-21 2004-01-06 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
AU2003266931B2 (en) * 2002-09-30 2010-01-21 Bayer Healthcare Llc FVII or FVIIa variants having increased clotting activity
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
CN1761747A (zh) 2003-03-18 2006-04-19 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
AU2004241698A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
CN1839203B (zh) * 2003-06-19 2011-11-16 拜耳医药保健有限公司 因子VII或VIIa的GLA结构域变体
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
ATE547519T1 (de) * 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
CA2546580A1 (en) * 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
TR201809670T4 (tr) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları.
WO2005075635A2 (en) * 2004-02-03 2005-08-18 Novo Nordisk Health Care Ag Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
JP2009508510A (ja) * 2005-09-21 2009-03-05 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2004214B1 (de) * 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Lokale behandlung mit faktor vii
JP2009543841A (ja) * 2006-07-17 2009-12-10 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
EP2147096B1 (de) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen davon
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
FI882746A (fi) * 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors

Also Published As

Publication number Publication date
AU7300291A (en) 1991-08-21
EP0521873A1 (de) 1993-01-13
JP2002247996A (ja) 2002-09-03
ATE180834T1 (de) 1999-06-15
JPH05500161A (ja) 1993-01-21
DE69131292D1 (de) 1999-07-08
CA2074839A1 (en) 1991-07-30
JP3330932B2 (ja) 2002-10-07
WO1991011514A1 (en) 1991-08-08
AU651573B2 (en) 1994-07-28
US5288629A (en) 1994-02-22
EP0521873B1 (de) 1999-06-02
CA2074839C (en) 2000-11-14
EP0521873A4 (en) 1993-05-05
US5824639A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
DE69131292D1 (de) Antikoagulierende proteine
Elg et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
CA1244763A (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
Elg et al. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
AU563925B2 (en) Removal of lipid containing virus in blood
Bajwa et al. Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes
CA2060507A1 (en) Factor xa based anticoagulant compositions
Gitel et al. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications
US5922358A (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
Aronson Factor IX complex
US5637299A (en) Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
Nagaki et al. Inactivator of the First Component of Human Complement (CĪINA) Enhancement of CĪlNA Activity against CĪs by Acidic Mucopolysaccharides
Weinstein et al. Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction.
US5510248A (en) Stable recombinant meizothrombin-like polypeptides
Prentice et al. Studies on the anticoagulant action of aprotinin (“Trasylol”)
Ku et al. Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin.
Seegers et al. Autocatalysis in prothrombin activation
Pejler Procoagulant and anticoagulant activities of resident and inflammatory peritoneal cells
CN109316599A (zh) 一种抑肽酶或其突变体、衍生物、类似物或其组成片段的应用
Latallo et al. Fibrinolytic system of guinea pig serum
JPH07291999A (ja) 血小板安定化因子ｉｘ−フラグメント、その製造方法及びこれを含有する薬剤
Thelin et al. The action of thrombin on serum albumin
EP0326013A3 (de) Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
Chamone Physiological aspects and clinical application of heparin
WO2000074711A2 (en) 10-formyltetrahydrofolate dehydrogenase as therapeutical agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8339 Ceased/non-payment of the annual fee